The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma
作者： Özlem Erdem , Ayşe Dursun , Uğur Coşkun , Nazan Günel
DOI: 10.1177/030089160509100109
关键词: Internal medicine 、 Carcinoma 、 Lymph 、 Oncology 、 Breast carcinoma 、 Survival analysis 、 Pathology 、 Ductal Breast Carcinoma 、 Immunohistochemistry 、 CD34 、 Neovascularization 、 Medicine
摘要: AIMS AND BACKGROUND p53, c-erbB-2 and Ki-67 protein expression microvessel density (MVD) determined by CD34 antibody were evaluated immunohistochemistry their correlation with clinicopathological parameters including estrogen (ER) progesterone (PR) receptor status survival investigated in patients axillary lymph node-negative infiltrating ductal breast carcinoma. METHODS The study population consisted of 47 RESULTS p53 was detected 36.2% 31.9% patients, respectively. Median 10%. There no statistically significant differences the distribution relation to age or size, histological grade ER PR tumors. correlated positively (P < 0.05). mean MVD 63.65 +/- 29.1 it Survival analysis revealed that age, tumor had prognostic impact, whereas grade, proliferative activity angiogenic factors. Although ER-positive a overall advantage, difference disease-free not significant. CONCLUSION In carcinoma could be useful indicators.
sci-hub.se 参考文章(34)
Climent Ma, Bellmunt J, Gimenez N, Ballesta Am, Segui Ma, Fernandez M, Albanelll J, Miralles M, Iglesias E, Perez-Picañol E, Molina R, Alonso C, Jo J, Filella X, Peiro G, p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Research. ,vol. 18, pp. 507- 511 ,(1998)
Early Breast Cancer Trialist's Collaborative Group, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. The Lancet. ,(1992) , 10.1016/0140-6736(92)90997-H
Wenche Reed, Einar Hannisdal, Per Johannes Boehler, Stein Gundersen, Herman Host, Jahn Marthin Nesland, The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer. ,vol. 88, pp. 804- 813 ,(2000) , 10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-Y
T. Mitsudomi, J. D. Minna, J. D. Minna, M. M. Nau, D. S. Liscia, G. R. Merlo, R. J. Osborne, I. Chiba, R. Callahan, T. Takahashi, T. Venesio, A. P M Cappa, Mutations in the p53 gene in primary human breast cancers. Cancer Research. ,vol. 51, pp. 6194- 6198 ,(1991)
Jeff Boyd, Molecular medicine quietly comes of age. New opportunities in the treatment of patients with breast cancer Cancer. ,vol. 74, pp. 2215- 2217 ,(1994) , 10.1002/1097-0142(19941015)74:8<2215::AID-CNCR2820740802>3.0.CO;2-E
Stephen B. Fox, Russell D Leek, Kenneth Smith, Justine Hollyer, Michael Greenall, Adrian L. Harris, Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Research and Treatment. ,vol. 29, pp. 109- 116 ,(1994) , 10.1007/BF00666186
Richard M. Elledge, D. Craig Allred, The p53 tumor suppressor gene in breast cancer. Breast Cancer Research and Treatment. ,vol. 32, pp. 39- 47 ,(1994) , 10.1007/BF00666204
LYDIA L. NAKOPOULOU, ANASTASIA ALEXIADOU, GEORGE E. THEODOROPOULOS, ANDREAS CH. LAZARIS, ANASTASIA TZONOU, ANDONIS KERAMOPOULOS, Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. The Journal of Pathology. ,vol. 179, pp. 31- 38 ,(1996) , 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O
B. Lampe, P. Hantschmann, T. Dimpfl, Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer. Archives of Gynecology and Obstetrics. ,vol. 261, pp. 139- 146 ,(1998) , 10.1007/S004040050213
Frederic Clayton, Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer. ,vol. 68, pp. 1309- 1317 ,(1991) , 10.1002/1097-0142(19910915)68:6<1309::AID-CNCR2820680621>3.0.CO;2-I